NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension - PubMed (original) (raw)

Comparative Study

NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension

M Oka et al. J Appl Physiol (1985). 1993 Sep.

Abstract

To determine if NIP-121, a new antihypertensive agent with K+ channel-opening activity, would be an effective vasodilator in pulmonary hypertension, we studied its acute hemodynamic effects under normoxic conditions in conscious chronically hypoxic pulmonary hypertensive rats and in control pulmonary normotensive rats. In contrast to no pulmonary vasodilation by NIP-121 in control rats, the K+ channel activator (10-100 mg/kg i.v.) decreased both mean pulmonary arterial pressure (from 42 +/- 2 to 33 +/- 2 mmHg; P < 0.05) and total pulmonary resistance (from 278 +/- 30 to 213 +/- 32 mmHg.l-1 x min; P < 0.05) in hypertensive rats. NIP-121 produced similar dose-related decreases in mean systemic arterial pressure and total systemic resistance in both groups of rats. Both the pulmonary and the systemic vasodilations to NIP-121 were inhibited by pretreatment with the blocker of ATP-sensitive K+ channels, glibenclamide (20 mg/kg), but not with the inhibitor of endothelium-derived relaxing factor synthesis, nitro-L-arginine (10 mg/kg). The L-type voltage-gated Ca2+ channel blocker, nifedipine (10-1,000 mg/kg i.v.), failed to cause pulmonary vasodilation in normoxic hypertensive rats, although there was dose-related systemic vasodilation. These results show that in contrast to the Ca2+ channel blocker, nifedipine, the K+ channel activator, NIP-121, is a potent vasodilator of chronic hypoxia-induced pulmonary hypertension in the rat. The mechanism of its hypotensive action in the hypertensive pulmonary vasculature might be more than simply membrane hyperpolarization and indirect inhibition of the L-type voltage-gated Ca2+ channel.

PubMed Disclaimer

Cited by

Noggin inhibits hypoxia-induced proliferation by targeting store-operated calcium entry and transient receptor potential cation channels.
Yang K, Lu W, Jia J, Zhang J, Zhao M, Wang S, Jiang H, Xu L, Wang J. Yang K, et al. Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C869-78. doi: 10.1152/ajpcell.00349.2014. Epub 2015 Mar 4. Am J Physiol Cell Physiol. 2015. PMID: 25740156 Free PMC article.
In vivo and in vitro measurements of pulmonary arterial stiffness: A brief review.
Tian L, Chesler NC. Tian L, et al. Pulm Circ. 2012 Oct;2(4):505-17. doi: 10.4103/2045-8932.105040. Pulm Circ. 2012. PMID: 23372936 Free PMC article.
K(ATP) channel therapeutics at the bedside.
Jahangir A, Terzic A. Jahangir A, et al. J Mol Cell Cardiol. 2005 Jul;39(1):99-112. doi: 10.1016/j.yjmcc.2005.04.006. J Mol Cell Cardiol. 2005. PMID: 15953614 Free PMC article. Review.
Recognition and management of pulmonary hypertension.
Wanstall JC, Jeffery TK. Wanstall JC, et al. Drugs. 1998 Dec;56(6):989-1007. doi: 10.2165/00003495-199856060-00004. Drugs. 1998. PMID: 9878988 Review.
Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series).
Maron BA, Machado RF, Shimoda L. Maron BA, et al. Pulm Circ. 2016 Dec;6(4):426-438. doi: 10.1086/688315. Pulm Circ. 2016. PMID: 28090285 Free PMC article. Review.

NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension - PubMed (original) (raw)